Dexcom Inc Stock Performance
| DXCM Stock | USD 73.38 2.68 3.79% |
The firm shows a Beta (market volatility) of 1.18, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, DexCom will likely underperform. At this point, DexCom Inc has a negative expected return of -0.0244%. Please make sure to confirm DexCom's value at risk, accumulation distribution, as well as the relationship between the Accumulation Distribution and day typical price , to decide if DexCom Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days DexCom Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy fundamental indicators, DexCom is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 4.06 | Five Day Return 7.26 | Year To Date Return (6.28) | Ten Year Return 363.87 | All Time Return 2.4 K |
Last Split Factor 4:1 | Last Split Date 2022-06-13 |
1 | Acquisition by Kevin Sayer of 68503 shares of DexCom subject to Rule 16b-3 | 01/28/2025 |
2 | Is DexCom, Inc. the Best Medical Device Stock to Buy | 02/12/2025 |
3 | DexCom Inc Trading 5.98 percent Higher on Feb 14 | 02/14/2025 |
4 | Bradley Foster Sargent Inc. CT Acquires New Shares in DexCom, Inc. | 02/24/2025 |
5 | Commerzbank Aktiengesellschaft FI Invests 225,000 in DexCom, Inc. | 03/06/2025 |
6 | Ethos Financial Group LLC Buys Shares of 6,925 DexCom, Inc. | 03/07/2025 |
7 | Vestmark Advisory Solutions Inc. Reduces Stock Holdings in DexCom, Inc. | 03/10/2025 |
8 | Healthy Returns Wegovy is linked to an increased risk of hair loss, study suggests | 03/11/2025 |
9 | GC Wealth Management RIA LLC Has 213,000 Position in DexCom, Inc. | 03/12/2025 |
10 | Looking At DexComs Recent Unusual Options Activity | 03/14/2025 |
11 | DexCom, Inc. Among the Best Diabetes Stocks to Buy According to Billionaires | 03/18/2025 |
| Begin Period Cash Flow | 567.5 M |
DexCom |
DexCom Relative Risk vs. Return Landscape
If you would invest 7,582 in DexCom Inc on December 19, 2024 and sell it today you would lose (244.00) from holding DexCom Inc or give up 3.22% of portfolio value over 90 days. DexCom Inc is currently does not generate positive expected returns and assumes 2.4673% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than DexCom, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
DexCom Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for DexCom's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as DexCom Inc, and traders can use it to determine the average amount a DexCom's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0099
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DXCM |
Estimated Market Risk
| 2.47 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average DexCom is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of DexCom by adding DexCom to a well-diversified portfolio.
DexCom Fundamentals Growth
DexCom Stock prices reflect investors' perceptions of the future prospects and financial health of DexCom, and DexCom fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DexCom Stock performance.
| Return On Equity | 0.28 | ||||
| Return On Asset | 0.0588 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 27.89 B | ||||
| Shares Outstanding | 390.77 M | ||||
| Price To Earning | 245.31 X | ||||
| Price To Book | 13.26 X | ||||
| Price To Sales | 6.85 X | ||||
| Revenue | 4.03 B | ||||
| Gross Profit | 2.44 B | ||||
| EBITDA | 840.7 M | ||||
| Net Income | 576.2 M | ||||
| Cash And Equivalents | 2.37 B | ||||
| Cash Per Share | 6.14 X | ||||
| Total Debt | 2.53 B | ||||
| Debt To Equity | 1.17 % | ||||
| Current Ratio | 3.77 X | ||||
| Book Value Per Share | 5.38 X | ||||
| Cash Flow From Operations | 989.5 M | ||||
| Earnings Per Share | 1.42 X | ||||
| Market Capitalization | 27.63 B | ||||
| Total Asset | 6.48 B | ||||
| Retained Earnings | 1.6 B | ||||
| Working Capital | 1.37 B | ||||
| Current Asset | 231.3 M | ||||
| Current Liabilities | 66.9 M | ||||
About DexCom Performance
By examining DexCom's fundamental ratios, stakeholders can obtain critical insights into DexCom's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that DexCom is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 126.36 | 68.46 | |
| Return On Tangible Assets | 0.09 | 0.10 | |
| Return On Capital Employed | 0.17 | 0.18 | |
| Return On Assets | 0.09 | 0.09 | |
| Return On Equity | 0.27 | 0.29 |
Things to note about DexCom Inc performance evaluation
Checking the ongoing alerts about DexCom for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DexCom Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| DexCom Inc generated a negative expected return over the last 90 days | |
| DexCom Inc is unlikely to experience financial distress in the next 2 years | |
| DexCom Inc has a strong financial position based on the latest SEC filings | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from insidermonkey.com: DexCom, Inc. Among the Best Diabetes Stocks to Buy According to Billionaires |
- Analyzing DexCom's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DexCom's stock is overvalued or undervalued compared to its peers.
- Examining DexCom's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DexCom's management team can have a significant impact on its success or failure. Reviewing the track record and experience of DexCom's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DexCom's stock. These opinions can provide insight into DexCom's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.39) | Earnings Share 1.42 | Revenue Per Share | Quarterly Revenue Growth 0.076 | Return On Assets |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.